insight bellu kol meet increas pt given
catalyst
morn bellu blu host kol meet professor jacki smith discuss
chronic cough landscap provid updat addit highlight need
safe effect therapi addict sedat professor smith express optim
select antagonist bellu also announc start screen
patient placebo-control phase ii dose-escal crossov trial relief assess
reduct awak cough frequenc unexplained/refractori chronic cough
patient top-lin data relief expect like serv major catalyst
compani
phase ii studi underway increas price target account major
inflect point month slight increas po follow initi result shionogi
select antagonist slightli de-risk drug class given view kol
merck nyse antagonist could work number indic outsid
chronic cough remain area substanti unmet need similar heard
live kol call professor smith emphas chronic cough debilit diseas
underappreci gener commun diseas take substanti toll
patient physic social psycholog perspect addit fatigu chest pain
headach nausea femal patient make total patient
popul also experi urinari incontin given lack novel approv therapi
last fifti year refractory/idiopath chronic cough remain area high unmet need
outsid non-pharmacolog therapi like speech patholog behavior therapi physician
left prescrib opiat benzonat neuromodul pregabalin/gabapentin
associ meaning dextromethorphan shown consist efficaci
market chronic cough may also larger model indic would provid
addit upsid bellu event bluestar bioadvisor third-parti consult group
review market analysi estim primari address chronic cough
patient diagnos year inclus criteria clinic trial also
note secondari patient diagnos greater eight week
less one year professor smith note clear pathophysiolog differ
year year patient popul investor day merck also estim
global chronic cough preval refractori idiopath true
larger estim use model bluestar bioadvisor merck
anticip mani restrict class payer enforc label
mid phase ii result chronic cough
year left
short interest float
financi cad
analyst certif disclosur pleas see page
potenti best-in-class antagonist still debat surround role vs
refractory/idiopath chronic cough professor smith note increasingli optimist potenti select antagonist
part base shionogi phase iia data detail addit professor smith note patient experienc tast
effect phase iib studi gefapix experi signific reduct cough frequenc compar
tast effect seem impli receptor primari driver cough hypersensit wherea receptor affect tast
public detail expect soon
given enhanc select compar gefapix professor smith believ asset potenti
mitig cough frequenc similar extent gefapix minim tast effect far safety/toler profil
look good phase studi one subject report tast alter expect therapeut dose bid
significantli better seen gefapix figur incid tast alter common higher dose like
coincid degre inhibit receptor
multipl drug class develop treatment refractory/idiopath chronic cough antagonist
one demonstr benefit clinic thu far american cough confer data present show gsk
nyse gsk modul nerr privat orvepit fail reduc cough frequenc
versu placebo recent attenua privat nicotin receptor antagonist fail phase ii trial
figur indirect comparison tast gefapix
phase ii studi design bellu offici begun screen patient random placebo-control phase ii dose-escal crossov
trial relief assess safeti efficaci unexplained/refractori chronic cough patient across
trial site us uk four dose level bid select antagonist test escal
day interv shown figur studi monitor awak cough frequenc similar endpoint use gefapix
phase iib studi cough frequenc prefer regulatori bodi addit patient undergo two-week screen
period follow-up period determin cough frequenc pre- post-treat top-lin result studi anticip
note professor smith pi trial
potenti indic expans addit develop refractory/unexplain chronic cough
bellu believ asset may appli multipl sensori disord given role receptor number sympathet pathway
compani specifi next indic look note anoth phase ii trial could initi sometim
next year remind merck also highlight gefapix broad potenti investor day compani current run phase iia studi
gefapix endometriosis-rel pain note posit signal sleep apnea well
twelve-month price target base dcf valuat assum wacc prior termin growth rate
million fulli dilut share pro-forma po prior potenti upsid model includ better expect
clinic result could requir us boost peak penetr probabl success relev indic expans
addit indic potenti success earlier anticip regulatori approv sale surpass
expect patent extens
risk price target includ wors expect clinic result unforeseen competit emerg
initi target indic chang regulatori environ market downturn potenti dilut financ
alpha seri
lifesci capit alpha seri intend encompass high conviction/impact idea within healthcar sector analys
recommend base deep fundament analysi goal help creat alpha investor long run
research analyst denot ac cover report certifi multipl research analyst primarili respons
report research analyst denot ac cover within document individu certifi respect secur subject
compani research analyst cover research view express report accur reflect person view
subject secur subject compani part research analyst compens directli
indirectli relat specif recommend view express research analyst report
